Coherus BioSciences, Inc.

CHRS | $2.19 0.46% 0.46% 810K

(0.0% 1d) (-4.4% 1m) (-72.0% 1y) (0.0% 2d) (0.0% 3d) (5.3% 7d) (-45.87% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 248,561,529
http://www.coherus.com
Sec Filling | Patents | 291 employees

(US) Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

add to watch list Paper trade email alert is off

Press-releases

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
Published: 2024-04-08 (Crawled : 12:30) - globenewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M

Health Technology

| 0.96% | O: 0.77% H: 1.63% C: 0.35%
CHRS | $2.19 0.46% 0.46% 810K

Health Technology

| -10.29% | O: 0.82% H: 3.88% C: 2.45%
chs-1000 preclinical for meeting

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Published: 2024-03-13 (Crawled : 20:00) - globenewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M

Health Technology

| -5.74% | O: 0.25% H: 0.0% C: 0.0%
CHRS | $2.19 0.46% 0.46% 810K

Health Technology

| -5.22% | O: -8.7% H: 21.43% C: 3.33%
business year update financial

INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Published: 2024-03-06 (Crawled : 21:00) - prnewswire.com
INO | $10.34 3.19% 3.09% 240K

Health Technology

| 5.07% | O: -2.23% H: 0.62% C: -6.42%
CHRS | $2.19 0.46% 0.46% 810K

Health Technology

| -1.36% | O: 0.45% H: 1.13% C: -0.45%
year financial results

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
CHRS | $2.19 0.46% 0.46% 810K

Health Technology

| 0.0% | O: 2.29% H: 4.04% C: -0.9%
report year financial results

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
Published: 2024-03-04 (Crawled : 06:00) - globenewswire.com
CHRS | $2.19 0.46% 0.46% 810K

Health Technology

| -9.54% | O: 5.39% H: 0.0% C: -10.63%
cimerli biosimilar business market

Coherus Completes Divestiture of Ophthalmology Franchise
Published: 2024-03-04 (Crawled : 06:00) - globenewswire.com
CHRS | $2.19 0.46% 0.46% 810K

Health Technology

| -9.54% | O: 5.39% H: 0.0% C: -10.63%

Coherus BioSciences Announces New Employment Inducement Grants
Published: 2024-02-23 (Crawled : 23:00) - globenewswire.com
CHRS | $2.19 0.46% 0.46% 810K

Health Technology

| Email alert Add to watchlist
grants

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
Published: 2024-02-21 (Crawled : 14:00) - globenewswire.com
CHRS | $2.19 0.46% 0.46% 810K

Health Technology

| -15.83% | O: -2.7% H: 2.38% C: -1.59%
udenyca system

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
Published: 2024-02-21 (Crawled : 13:00) - globenewswire.com
VCNX | $4.94 -2.76% 7.4K

Health Technology

| -40.88% | O: 9.89% H: 9.54% C: -4.01%
CHRS | $2.19 0.46% 0.46% 810K

Health Technology

| -15.83% | O: -2.7% H: 2.38% C: -1.59%
activmab technology virus

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
CHRS | $2.19 0.46% 0.46% 810K

Health Technology

| 5.83% | O: -3.4% H: 4.52% C: 1.51%
agreement

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001610717-24-000060	4	2024-02-16	2024-02-09	Buy	G	99988	99988
0001610717-24-000060	4	2024-02-16	2024-02-09	Sell	G	99988	0